Brief: Celyad Announces Strategic Updates To The Autologous R/R Aml And Mds Program

Celyad Oncology SA

01/07/2019 21:08

July 1 (Reuters) - Celyad SA  CYAD.BR :
    * CELYAD ANNOUNCES STRATEGIC UPDATES TO THE AUTOLOGOUS R/R
AML AND
MDS PROGRAM
    * CELYAD SA - FDA ACCEPTED INVESTIGATIONAL NEW DRUG
APPLICATION TO
COMMENCE CLINICAL TRIALS FOR NEXT-GENERATION, CAR-T CANDIDATE,
CYAD-02
    * CELYAD SA - FDA AND FAMHP ACCEPTED PROPOSAL TO UTILIZE
NEW,
PROPRIETARY 'OPTIMAB' MANUFACTURING PROCESS FOR BOTH CYAD-01 AND
CYAD-02

Source text for Eikon:  ID:nGNX7GmMVQ 
Further company coverage:  CYAD.BR 

 ((Briefs@thomsonreuters.com;))